Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

The Lancet Diabetes & Endocrinology 2026

View at publisher

Authors: Daisuke Yabe, Toshihiko Shiraiwa, Hiroyuki Ugai, Masakazu Takeuchi, Ryo Suzuki

DOI: 10.1016/s2213-8587(26)00138-5

Cited by: 1

References: 28

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Metabolism and Cancer

References 28